Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 
• By Anju Ghangurde
  
growth opportunities
Dr Reddy's bets big on the GLP-1 segment (Shutterstock)

More from Focus On Asia

More from Scrip